A leading insolvency litigation financing company has said it is ‘delighted’ to report its highest ever revenue for the latest financial year. 

Manolete, which is UK-listed, announced its audited results for the year ended 31 March 2025 today, which showed record total revenue of £30.5m, an increase of 16% on the previous financial year.

It revealed there had been a record number (282) of new case investments in UK insolvency cases (excluding Bounce Back Loan Pilot ‘BBLP’) and a record number of 291 cases completed in FY25.

Steven Cooklin, chief executive, said: ‘We are delighted to report our highest ever revenues of £30.5m for FY25 and a strong increase in profitability, well ahead of market forecasts. 

‘Cash generation has also been particularly impressive with a 45% increase in gross cash receipts for the year. In FY25 we also recorded lifetime highs in the number of new case referrals from Manolete’s nationwide proprietary referral network. 

‘FY26 has got off to a strong start with new case signings already 27% higher than the whole of Q1 FY25 and further concrete evidence of larger average case sizes feeding into our portfolio of more recent case signings. The continued strong tailwinds of challenging market conditions faced by many UK corporates provide the Board with optimism for further good progress in the new financial year.’

Manolete Partners Plc is a specialist insolvency litigation financing company which funds or buys insolvency claims. Its website states it will ‘build powerful partnerships with our Insolvency Practitioners and their solicitors to help maximise returns to creditors’.

UK business insolvencies were expected to hit a 12-year high last year, peaking at 43% above pre-covid levels, with sectors like construction, hospitality, and retail most affected, according to a report by international insurance company Allianz Trade. Businesses faced a series of shocks, from Brexit and the Covid-19 crisis, to rising interest rates sticky inflation and UK insolvencies are expected to stay 30% above pre-pandemic levels until 2026. 

 

This article is now closed for comment.